(MENAFN- Market Press Release) October 29, 2025 5:20 am - The global Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is projected to reach USD 8.25 billion by 2025, growing at a 3.5% CAGR through 2032.

Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market to Reach USD 8.25 Billion by 2025, Expanding at 3.5% CAGR Through 2032

The global Direct-Acting Antiviral (DAA) Therapies for Hepatitis C Market is projected to attain a valuation of USD 8,250 million in 2025, growing at a steady compound annual growth rate (CAGR) of 3.5% between 2025 and 2032. This growth is primarily driven by the increasing global prevalence of hepatitis C infections, expanding access to antiviral medications in developing countries, and the continuous introduction of more efficacious, shorter-duration oral regimens. North America, Europe, and Asia-Pacific remain key contributors, with growing screening programs and government-backed treatment initiatives further accelerating adoption.

Market Summary

Direct-Acting Antiviral (DAA) therapies have transformed the treatment paradigm for chronic hepatitis C, offering over 95% cure rates with improved safety and reduced treatment durations compared to traditional interferon-based therapies. By 2032, the global market is expected to exceed USD 10 billion, supported by increasing patient awareness, improved healthcare access, and national hepatitis elimination strategies. North America leads the market owing to robust reimbursement frameworks and the presence of major pharmaceutical companies, while Asia-Pacific shows the fastest growth due to large patient pools in China and India and improving diagnostic coverage.

Key Segment or Application Focus

The market is segmented based on drug class (NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors) and genotype coverage. The combination therapy segment, which targets multiple viral replication pathways, continues to dominate owing to its higher efficacy and lower relapse rates. Among applications, hospital pharmacies and retail distribution channels remain key due to expanded availability of oral DAA regimens. Rising demand for pangenotypic drugs-effective across all hepatitis C genotypes-is further reshaping the treatment landscape, especially in low- and middle-income countries.

Price Trend

The average price of DAA therapies declined moderately from 2024 to 2025, particularly in the United States, India, and Brazil, reflecting competitive market dynamics and expanded generic availability. U.S. prices fell by around 5–7% due to insurer negotiations and increasing generic entries. In India, government-led procurement programs led to a 10% reduction in average treatment cost, supporting broader access. Brazil also experienced lower prices following regional manufacturing partnerships. This trend is expected to continue as global efforts intensify toward affordable universal hepatitis C treatment.

Key Players Snapshot

Prominent industry participants include Gilead Sciences, Inc. (U.S.), AbbVie Inc. (U.S.), Bristol Myers Squibb (U.S.), Merck & Co., Inc. (U.S.), and Janssen Pharmaceuticals (Belgium). In Asia, Cipla Ltd. and Dr. Reddy's Laboratories Ltd. are notable for expanding generic DAA production. European firms such as Roche Holding AG and Novartis AG remain active through strategic collaborations and research programs targeting improved next-generation DAA formulations.

Request for customization

MENAFN30102025003520003262ID1110272826